DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
South Korea · Delayed Price · Currency is KRW 5,060.00
-230.00 (-4.35%)
At close: Mar 31, 2026
DongKoo Bio & Pharma Revenue
In the year 2025, DongKoo Bio & Pharma had annual revenue of 242.69B KRW, down -2.64%. DongKoo Bio & Pharma had revenue of 61.87B in the quarter ending December 31, 2025, with 7.47% growth.
Revenue
242.69B
Revenue Growth
-2.64%
P/S Ratio
0.59
Revenue / Employee
600.71M
Employees
404
Market Cap
142.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 242.69B | -6.59B | -2.64% |
| Dec 31, 2024 | 249.27B | 33.59B | 15.57% |
| Dec 31, 2023 | 215.69B | 20.70B | 10.62% |
| Dec 31, 2022 | 194.99B | 39.84B | 25.68% |
| Dec 31, 2021 | 155.15B | 15.93B | 11.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| H.PIO | 257.56B |
| Daehan Nupharm | 202.40B |
| Kyung Dong Pharmaceutical | 193.64B |
| HYUNDAI BIOLAND | 130.51B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 106.44B |
| KOREA PHARMA | 87.60B |
| Vivozon Pharmaceutical | 66.40B |
| Polaris AI Pharma | 63.94B |